ASTROCYTOMA

This study aims to find the safest schedule for giving radiation treatment to people whose glioblastoma brain tumors have returned after previous radiation. Researchers will test three different treatment lengths (1, 2, or 3 weeks) in 28 adults with recurrent grade 4 brain tumors…

This early-stage study is testing a new combination treatment for adults with aggressive brain cancer that has come back. After surgery to remove the tumor, doctors inject a specially engineered virus into the brain and give patients oral medications. This is followed by targeted…

This study is testing whether combining two drugs—an oral vitamin A derivative (ATRA) and an immunotherapy (retifanlimab)—can help control recurrent brain tumors called IDH-mutant gliomas. The goal is to see if this combination is safe and can shrink tumors or stop their growth. …

This study is testing the safety of an experimental virus therapy called G207 for children and young adults with recurrent or hard-to-treat brain tumors in the cerebellum. The virus is designed to infect and kill cancer cells while sparing healthy ones. Researchers will also test…

This study is testing whether the drug tuvusertib can help control recurrent brain tumors called astrocytomas that have specific genetic mutations. It will involve 56 adults whose cancer has returned after initial treatment. The main goal is to see if the drug can keep the cancer…

This study is testing if the blood-thinning medication apixaban can safely prevent dangerous blood clots in people newly diagnosed with aggressive brain tumors (grade 4 glioma). It will involve about 40 adult patients who are starting radiation and chemotherapy. The main goal is …

This study is testing a new psychological support program called FearLess, designed to help people with brain tumors and their caregivers manage the fear of the cancer coming back. Researchers want to see if the program is practical to run and acceptable to participants. The stud…